Detailed Narrative
Q1 FY27 Financial Performance Overview
MedPlus Health Services reported consolidated revenue of INR18,796 million for Q1 FY27. The consolidated operating EBITDA stood at INR651 million, translating to a margin of 3.5%. Pharmacy operations demonstrated strong growth, with revenue increasing by 21.8% year-on-year, and contributed INR588 million to operating EBITDA at a 3.2% margin. Diagnostics revenue also saw significant growth, reaching INR370.8 million compared to INR302.9 million in Q1 FY26, with its operating EBITDA rising to INR65.9 million from INR41.3 million in the prior year's comparable quarter.
Strategic Capex Plans Put on Hold
The company announced that previously approved capex proposals for a food park and a wellness services facility have been put on hold. This decision was influenced by market feedback and a re-evaluation of the strategy, as management acknowledged they might not be '100% right' on these diversification efforts. However, MedPlus clarified that capex for its core pharmacy business remains unaffected and will continue as planned, indicating a more focused approach on its primary operations.
Private Label Share Contraction and Recovery Strategy
Private label sales constituted 20% of total revenue in Q1 FY27, with pharma at 10.7% and non-pharma at 9.3%, representing a contraction from previous periods. Management attributed this to an initial aggressive push by employees and a subsequent shift to prioritize customer choice. The company aims to arrest this degrowth and gradually build up the private label share by 0.3% to 0.5% per quarter, expecting this to contribute to gross margin improvement.
Challenges and Adjustments in Franchisee Model
MedPlus reported 27 franchisee outlet closures during the quarter, with an average store age of only 0.7 years. Management identified an 'expectation mismatch' among first-time entrepreneurs as a key reason for these closures. In response, the company is implementing adjustments, such as providing support to help franchisees achieve breakeven faster, to improve the model's viability and reduce churn, while still targeting 800 net new stores for FY27, including franchisee outlets.
Rising Employee Costs and Mitigation Efforts
Employee expenses have seen a significant increase, particularly in Karnataka (60% rise) and Telangana (25% increase), driven by minimum wage hikes and the full-quarter impact of new warehouse staff. To mitigate these rising costs, MedPlus has stopped new sign-ups for its retention bonus plan, effective March 1st, and is actively optimizing non-statutory payments. This highlights a key cost pressure point the company is actively managing.
Diagnostics Business Outlook and Promoter Leverage
Despite strong Q1 FY27 performance, management indicated that the diagnostics business has not achieved the desired scale, especially in B2B/B2C subscription members, which remain around 2 lakh. Consequently, there are no plans for significant expansion in diagnostics, particularly the radiology segment, beyond maintenance. Separately, the company acknowledged promoter debt of approximately INR1,150 crores, stating that the family office is actively looking into reduction strategies, but no concrete plan or timeline has been disclosed yet.